**2-(3'-methoxy-4'-hydroxybenzylidene)cyclopentene-1,3-dione** is a chemical compound, often referred to by its abbreviated name **MHBD**. It's a derivative of cyclopentenedione, a molecule with a unique structure that makes it a valuable component in various research areas.
**Structure and Properties:**
* **Cyclopentenedione:** The core structure of MHBD is cyclopentenedione, a five-membered ring containing two carbonyl groups (C=O) adjacent to each other. This arrangement makes the molecule highly reactive and prone to various chemical transformations.
* **Benzylidene:** The molecule is substituted with a benzylidene group (C=CH-Ph) at the 2-position. This group is derived from benzaldehyde, a fragrant aromatic aldehyde, and adds to the compound's aromatic character.
* **Methoxy and Hydroxy Groups:** At the 3' and 4' positions on the benzene ring, there are methoxy (-OCH3) and hydroxy (-OH) groups. These groups are important for the compound's biological activity.
**Research Importance:**
MHBD is a key molecule in research for several reasons:
* **Antioxidant Activity:** MHBD exhibits significant antioxidant properties due to the presence of the hydroxy group. Antioxidants are vital in protecting cells from damage caused by free radicals, which can contribute to aging and disease.
* **Anti-inflammatory Properties:** Studies have shown that MHBD has anti-inflammatory effects. This property makes it a promising candidate for treating conditions like arthritis, inflammatory bowel disease, and other inflammatory disorders.
* **Anti-cancer Potential:** MHBD is being investigated for its potential to combat cancer. It has shown promise in inhibiting the growth of various cancer cell lines, potentially through mechanisms involving cell cycle arrest and apoptosis.
* **Potential for Drug Development:** The unique chemical structure of MHBD and its observed biological activities make it a promising lead molecule for the development of new drugs targeting a range of diseases.
**Research Areas:**
MHBD is being researched in various fields, including:
* **Pharmacology:** Studying its mechanisms of action, identifying its potential therapeutic applications, and optimizing its pharmacological properties.
* **Chemistry:** Exploring its synthetic pathways, modifying its structure to enhance its desired effects, and investigating its reactivity.
* **Biology:** Understanding its interactions with biological systems, including its effects on cellular pathways and signaling.
**Note:** While research on MHBD is promising, it's important to note that it's still in the early stages of development. Further research is necessary to confirm its safety and efficacy for therapeutic use.
2-(3'-methoxy-4'-hydroxybenzylidene)cyclopentene-1,3-dione: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 99844 |
CHEMBL ID | 2133790 |
MeSH ID | M0153338 |
Synonym |
---|
4-cyclopentene-1,3-dione, 2-((4-hydroxy-3-methoxyphenyl)methylene)- |
nsc-239309 |
mls003389314 , |
55776-43-7 |
nsc239309 |
khi 201 |
2-[(4-hydroxy-3-methoxyphenyl)methylidene]cyclopent-4-ene-1,3-dione |
smr002048969 |
2-(3'-methoxy-4'-hydroxybenzylidene)cyclopentene-1,3-dione |
khi-201 |
nsc 239309 |
CHEMBL2133790 |
DTXSID50971150 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glp-1 receptor, partial | Homo sapiens (human) | Potency | 19.9526 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
WRN | Homo sapiens (human) | Potency | 10.0000 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
TDP1 protein | Homo sapiens (human) | Potency | 0.2114 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 11.2202 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 1.9307 | 0.2239 | 11.2451 | 35.4813 | AID624173; AID720569; AID720584 |
67.9K protein | Vaccinia virus | Potency | 13.1311 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
IDH1 | Homo sapiens (human) | Potency | 14.5810 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 125.8920 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 5.3233 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
Vpr | Human immunodeficiency virus 1 | Potency | 1.9953 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 79.4328 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
Alpha-synuclein | Homo sapiens (human) | Potency | 1.0000 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 0.6310 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 84.3679 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
PAX8 | Homo sapiens (human) | AC50 | 0.9450 | 0.0488 | 5.4354 | 69.1700 | AID687027; AID687029 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1145208 | Antitumor activity against mouse ascites Sarcoma 180 cells allografted in ddN mouse assessed as percentage of total packed cell volume ratio at 3 mg/kg/day for 5 days administered 24 hrs after tumor inoculation measured 7th day after tumor inoculation | 1976 | Journal of medicinal chemistry, Mar, Volume: 19, Issue:3 | Structure and antitumor activity relationship of 2-arylidene-4-cyclopentene-1, 3-diones and 2-arylideneindan-1, 3-diones. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |